Posted by Michael Wonder on 09 Nov 2019
Xeomin Cosmetic licensed for additional indications In Canada
7 November 2019 - Merz Pharma has announced that Health Canada has provided marketing authorization for additional indications for Xeomin Cosmetic (botulinum toxin type A, free from complexing proteins), which include use in adults for the temporary improvement in the appearance of moderate to severe horizontal forehead lines and lateral canthal lines (crow's feet).
The additional indications build upon the previous indication for the temporary improvement in the appearance of moderate-to-severe glabellar lines, also known as frown lines, between the eyebrows, in adult patients.
